HealthMore in Health→
New obesity drug data raises questions about Boehringer’s positioning
Key Takeaways
- The available summary describes a mixed data readout for Boehringer’s obesity drug.
- The strongest positive signal mentioned is reduced liver fat.
- The weaker point is less impressive overall weight loss.
- Without fuller published details, competitiveness remains the main open question.
DE
DT Editorial Team··via statnews.com
